141 related articles for article (PubMed ID: 38712289)
21. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
Gehlhausen JR; Park SJ; Hickox AE; Shew M; Staser K; Rhodes SD; Menon K; Lajiness JD; Mwanthi M; Yang X; Yuan J; Territo P; Hutchins G; Nalepa G; Yang FC; Conway SJ; Heinz MG; Stemmer-Rachamimov A; Yates CW; Wade Clapp D
Hum Mol Genet; 2015 Jan; 24(1):1-8. PubMed ID: 25113746
[TBL] [Abstract][Full Text] [Related]
22. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas.
Mérel P; Hoang-Xuan K; Sanson M; Moreau-Aubry A; Bijlsma EK; Lazaro C; Moisan JP; Resche F; Nishisho I; Estivill X
Genes Chromosomes Cancer; 1995 Jul; 13(3):211-6. PubMed ID: 7669741
[TBL] [Abstract][Full Text] [Related]
23. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.
Ng HK; Lau KM; Tse JY; Lo KW; Wong JH; Poon WS; Huang DP
Neurosurgery; 1995 Oct; 37(4):764-73. PubMed ID: 8559307
[TBL] [Abstract][Full Text] [Related]
24. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.
Giovannini M; Robanus-Maandag E; van der Valk M; Niwa-Kawakita M; Abramowski V; Goutebroze L; Woodruff JM; Berns A; Thomas G
Genes Dev; 2000 Jul; 14(13):1617-30. PubMed ID: 10887156
[TBL] [Abstract][Full Text] [Related]
25. [Retinal Astrocytic Hamartoma in Neurofibromatosis Type 2 - Metaanalysis and a Case Report].
Starosta DA; Lorenz B
Klin Monbl Augenheilkd; 2018 Mar; 235(3):290-300. PubMed ID: 29534265
[TBL] [Abstract][Full Text] [Related]
26. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.
Ruggieri M; Praticò AD; Serra A; Maiolino L; Cocuzza S; Di Mauro P; Licciardello L; Milone P; Privitera G; Belfiore G; Di Pietro M; Di Raimondo F; Romano A; Chiarenza A; Muglia M; Polizzi A; Evans DG
Acta Otorhinolaryngol Ital; 2016 Oct; 36(5):345-367. PubMed ID: 27958595
[TBL] [Abstract][Full Text] [Related]
27. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
[TBL] [Abstract][Full Text] [Related]
28. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?
Kley N; Seizinger BR
Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520
[TBL] [Abstract][Full Text] [Related]
29. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu-Emerson C; Plotkin SR
Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
[TBL] [Abstract][Full Text] [Related]
30. Management of multiple tumors in neurofibromatosis type 2 patients.
Aboukais R; Bonne NX; Baroncini M; Zairi F; Schapira S; Vincent C; Lejeune JP
Neurochirurgie; 2018 Nov; 64(5):364-369. PubMed ID: 26071178
[TBL] [Abstract][Full Text] [Related]
31. Mutations and allelic loss of the NF2 gene in neurofibromatosis 2-associated skin tumors.
Kluwe L; Friedrich RE; Hagel C; Lindenau M; Mautner VF
J Invest Dermatol; 2000 May; 114(5):1017-21. PubMed ID: 10771486
[TBL] [Abstract][Full Text] [Related]
32. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2.
Stemmer-Rachamimov AO; Ino Y; Lim ZY; Jacoby LB; MacCollin M; Gusella JF; Ramesh V; Louis DN
J Neuropathol Exp Neurol; 1998 Dec; 57(12):1164-7. PubMed ID: 9862639
[TBL] [Abstract][Full Text] [Related]
33. Neurofibromatosis.
Korf BR
Handb Clin Neurol; 2013; 111():333-40. PubMed ID: 23622184
[TBL] [Abstract][Full Text] [Related]
34. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development.
Shin J; Padmanabhan A; de Groh ED; Lee JS; Haidar S; Dahlberg S; Guo F; He S; Wolman MA; Granato M; Lawson ND; Wolfe SA; Kim SH; Solnica-Krezel L; Kanki JP; Ligon KL; Epstein JA; Look AT
Dis Model Mech; 2012 Nov; 5(6):881-94. PubMed ID: 22773753
[TBL] [Abstract][Full Text] [Related]
35. An update on the CNS manifestations of neurofibromatosis type 2.
Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
[TBL] [Abstract][Full Text] [Related]
36. NF2: the wizardry of merlin.
Xiao GH; Chernoff J; Testa JR
Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
[TBL] [Abstract][Full Text] [Related]
37. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma.
Chiasson-MacKenzie C; Vitte J; Liu CH; Wright EA; Flynn EA; Stott SL; Giovannini M; McClatchey AI
Nat Commun; 2023 Mar; 14(1):1559. PubMed ID: 36944680
[TBL] [Abstract][Full Text] [Related]
38. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma.
Irving RM; Moffat DA; Hardy DG; Barton DE; Xuereb JH; Maher ER
Hum Mol Genet; 1994 Feb; 3(2):347-50. PubMed ID: 8004107
[TBL] [Abstract][Full Text] [Related]
39. Proliferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling.
Antinheimo J; Haapasalo H; Seppälä M; Sainio M; Carpen O; Jääskeläinen J
J Neuropathol Exp Neurol; 1995 Nov; 54(6):776-82. PubMed ID: 7595650
[TBL] [Abstract][Full Text] [Related]
40. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
